Daratumumab

What is Daratumumab?

Daratumumab is a groundbreaking medication classified as a **monoclonal antibody**, primarily utilized in the treatment of **multiple myeloma**, a cancer of plasma cells. It represents a significant advancement in targeted cancer therapies. Approved by regulatory bodies such as the FDA, Daratumumab is marketed under brand names like Darzalex and Darzalex Faspro. This medication works by specifically targeting a protein called **CD38**, which is abundantly expressed on the surface of multiple myeloma cells, as well as on other immune cells.

Administered either intravenously (into a vein) or subcutaneously (under the skin), Daratumumab can be used as a standalone therapy (monotherapy) or, more commonly, in combination with other anti-myeloma drugs. Its introduction has significantly improved outcomes for patients with both newly diagnosed and relapsed/refractory multiple myeloma, offering a new avenue of treatment for those who may have exhausted other options.

How Does it Work?

The mechanism of action for Daratumumab is highly specific and multifaceted. As a human IgG1κ monoclonal antibody, it binds with high affinity to the CD38 glycoprotein. CD38 is a transmembrane protein that plays various roles, including cell adhesion, signal transduction, and enzymatic activity, and its high expression on multiple myeloma cells makes it an ideal therapeutic target.

Once Daratumumab binds to CD38 on the surface of myeloma cells, it initiates several powerful anti-tumor effects:

• Complement-Dependent Cytotoxicity (CDC): Daratumumab activates the complement system, a part of the immune system, leading to the lysis (destruction) of myeloma cells.
• Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC): Natural killer (NK) cells and other immune effector cells recognize the antibody-coated myeloma cells and directly kill them.
• Antibody-Dependent Cellular Phagocytosis (ADCP): Macrophages, another type of immune cell, engulf and destroy Daratumumab-coated myeloma cells.
• Direct Apoptosis: Daratumumab can directly induce programmed cell death (apoptosis) in CD38-expressing myeloma cells upon binding.
• Immunomodulatory Effects: By depleting CD38-positive immunosuppressive cells such as regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), and B cells, Daratumumab can enhance the overall anti-tumor immune response.

Through these combined mechanisms, Daratumumab effectively eliminates multiple myeloma cells, thereby controlling disease progression and improving patient prognosis.

Medical Uses

The primary medical use of Daratumumab is in the treatment of **multiple myeloma**. Its indications have expanded significantly since its initial approval:

• Newly Diagnosed Multiple Myeloma: Daratumumab is often used in combination with other agents (e.g., lenalidomide and dexamethasone; bortezomib, melphalan, and prednisone; or bortezomib, thalidomide, and dexamethasone) for patients who are transplant-eligible or ineligible.
• Relapsed/Refractory Multiple Myeloma: It is indicated for patients who have received prior therapy and whose disease has returned or is no longer responding to treatment. In this setting, it can be used as monotherapy or in combination with other drugs such such as lenalidomide and dexamethasone, pomalidomide and dexamethasone, or carfilzomib and dexamethasone.

The versatility of Daratumumab to be used across different lines of therapy, both as a single agent and in various combinations, underscores its importance in the evolving landscape of multiple myeloma treatment. Research is also exploring its potential role in other CD38-positive hematologic malignancies and conditions like amyloid light chain (AL) amyloidosis.

Dosage

The dosage and administration of Daratumumab vary depending on whether it's given intravenously (IV) or subcutaneously (SC), and the specific treatment regimen. For intravenous administration, the typical dose is 16 mg/kg of body weight. For subcutaneous administration, a fixed dose of 1800 mg is used, often co-formulated with recombinant human hyaluronidase for improved dispersion and absorption.

The treatment schedule typically involves weekly doses for the first several weeks, followed by bi-weekly doses, and then monthly doses, depending on the specific indication and combination therapy. A crucial aspect of Daratumumab administration, especially for the IV formulation, is the use of pre-medications. These typically include corticosteroids, antihistamines, and antipyretics, administered prior to each infusion to minimize the risk and severity of **infusion reactions**. Patients are closely monitored during and after administration for any signs of adverse reactions.

Side Effects

Like all medications, Daratumumab can cause side effects. The most common and notable adverse events are **infusion reactions**, which can occur during or within 24 hours of administration, particularly with the first few IV doses. These reactions can range from mild to severe and may include symptoms such as chills, fever, nausea, cough, shortness of breath, headache, and rash. Pre-medication helps to mitigate these.

Other common side effects include:

• Fatigue
• Nausea, diarrhea, or constipation
• Upper respiratory tract infections (e.g., bronchitis, pneumonia)
• Cough
• Peripheral neuropathy (especially when combined with bortezomib)
• Muscle spasms

More serious side effects can include:

• Severe infusion reactions, requiring medical intervention.
• Low blood counts (cytopenias), such as neutropenia (low white blood cells), thrombocytopenia (low platelets), and anemia (low red blood cells), increasing the risk of infection and bleeding.
• Increased risk of infections, including viral (e.g., herpes zoster reactivation) and bacterial infections.
• Hepatitis B virus reactivation in patients who are carriers.
• Interference with blood compatibility testing, due to CD38 expression on red blood cells, which can complicate blood transfusions.

Patients should report any new or worsening symptoms to their healthcare provider promptly.

Drug Interactions

While Daratumumab itself does not undergo significant hepatic metabolism or direct drug-drug interactions via cytochrome P450 enzymes, there are important considerations regarding its use with other medications.

• Immunosuppressants: Concurrent use with other immunosuppressive agents can further increase the risk of infections. Live attenuated vaccines should generally be avoided during Daratumumab treatment.
• Other Anti-Myeloma Agents: When used in combination with other anti-myeloma drugs (e.g., proteasome inhibitors, immunomodulatory drugs, corticosteroids), there may be additive toxicities, such as increased myelosuppression (low blood counts) or peripheral neuropathy. Careful monitoring and dose adjustments of concomitant medications may be necessary.
• Interference with Blood Transfusion Testing: One unique and clinically significant interaction is Daratumumab's interference with indirect antiglobulin tests (IAT), also known as antibody screening, in blood banks. Because CD38 is also present on red blood cells, Daratumumab can bind to these cells, causing a false positive reaction during pre-transfusion compatibility testing. It is crucial to inform the blood bank that a patient is receiving Daratumumab to ensure appropriate measures are taken for accurate blood typing and cross-matching, such as using dithiothreitol (DTT) treatment of red blood cells to disrupt CD38.

Patients should provide a complete list of all medications, supplements, and herbal products they are taking to their healthcare provider to avoid potential interactions.

FAQ

Q: What is Daratumumab used for?

A: Daratumumab is primarily used for the treatment of **multiple myeloma**, both in newly diagnosed patients and those with relapsed or refractory disease.

Q: How is Daratumumab administered?

A: It can be administered either intravenously (IV infusion) or subcutaneously (SC injection).

Q: What are the most common side effects of Daratumumab?

A: The most common side effects include **infusion reactions**, fatigue, nausea, and upper respiratory tract infections.

Q: Why is pre-medication necessary with Daratumumab?

A: Pre-medications (like corticosteroids, antihistamines, and antipyretics) are given to reduce the risk and severity of **infusion reactions**, which are common, especially with the first few doses.

Q: Can Daratumumab affect blood tests?

A: Yes, it can interfere with certain blood compatibility tests, making it crucial to inform blood banks if you are receiving this medication before a transfusion.

Q: Is Daratumumab a chemotherapy drug?

A: No, Daratumumab is not a traditional chemotherapy drug. It is a targeted **immunotherapy**, specifically a **monoclonal antibody**, that works by targeting specific proteins on cancer cells.

Products containing Daratumumab are available through trusted online pharmacies. You can browse Daratumumab-based medications at ShipperVIP or Medicenter.

Summary

Daratumumab stands as a pivotal **immunotherapy** in the management of **multiple myeloma**. Its innovative mechanism, involving specific targeting of the **CD38** protein on cancer cells, allows it to effectively eliminate myeloma cells through multiple immune-mediated pathways. This has translated into improved outcomes for patients across various stages of the disease.

While highly effective, patients receiving Daratumumab should be aware of potential side effects, particularly **infusion reactions**, and the importance of pre-medication. Furthermore, its unique interaction with blood compatibility testing highlights the need for close communication between patients, healthcare providers, and blood banks. Ongoing research continues to explore its full potential and optimal integration into complex treatment regimens for multiple myeloma and other conditions.